Literature DB >> 3371267

Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine.

J A Moore1, C G Rudman, N J MacLachlan, G B Fuller, B Burnett, J W Frane.   

Abstract

Two forms of human GH (hGH) have been produced by recombinant DNA technology. One form has an amino acid sequence identical to that of the natural pituitary hormone (rhGH) and the other form has an additional N-terminal methionine (Met-hGH). The biological potencies of these 2 polypeptides have been compared in hypophysectomized rats in a multidose study measuring body weights and several long bone growth parameters. The pharmacokinetic profiles after iv and sc injection were determined in cynomolgus monkeys in a 4-period cross-over study. All of the measured parameters in all the studies indicated that there was no difference in the two forms of hGH. Measurements taken after 27 daily injections of rhGH or Met-hGH (30-500 micrograms/kg.day) indicated that femur length and width of the proliferative zone in the tibial epiphysis showed dose-related effects for both forms of hGH but no difference between them. The relative potency, based on body weight gain, was calculated using a parallel line bioassay. Weight gain after 8 daily injections in the 5-dose long bone growth study indicated a rhGH potency of 0.80 (95% confidence interval, 0.5-1.23) relative to Met-hGH. It was concluded that the presence of an N-terminal methionine on hGH has no effect on potency in this model. The pharmacokinetic parameters after iv administration were estimated by fitting serum concentration-time data to a 2-compartment model. Parameters after sc injection were computed by compartment-independent methods. Met-hGH and rhGH had very similar pharmacokinetic profiles after both routes of administration. Comparison of the pharmacokinetic parameters indicated that the clearance after iv administration (rhGH, 15 ml/min; Met-hGH, 13 ml/min) and the sc bioavailability (rhGH, 0.72 +/- 0.21; Met-hGH, 0.59 +/- 0.21) were not significantly different for the 2 forms of hGH. It was concluded that rhGH and Met-hGH have equivalent bioavailability and pharmacokinetics in cynomolgus monkeys.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3371267     DOI: 10.1210/endo-122-6-2920

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  The level of bioavailable growth hormone (GH) after the first GH injection predicts the first year's growth response in GH-deficient children.

Authors:  M Bozzola; G Radetti; S Pagani; M Draghi; G Aimaretti; G Rondini
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

2.  Insulin-like growth factor-1 and growth hormone (GH) have distinct and overlapping anabolic effects in GH-deficient rats.

Authors:  R G Clark; D L Mortensen; L M Carlsson
Journal:  Endocrine       Date:  1995-04       Impact factor: 3.633

3.  Pharmacokinetics of radioiodinated human and ovine growth hormones in transgenic mice expressing bovine growth hormone.

Authors:  D Turyn; A Bartke
Journal:  Transgenic Res       Date:  1993-07       Impact factor: 2.788

4.  Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins.

Authors:  J Mordenti; S A Chen; J A Moore; B L Ferraiolo; J D Green
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

5.  Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.

Authors:  T Romer; F Peter; P Saenger; J Starzyk; B Koehler; E Korman; M Walczak; R Wasik; M Ginalska-Malinowska; E Solyom; A Berghout
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.